Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

Journal of Clinical Medicine

Ramya Kollipara²  Erfon Ekhlassi¹  Christopher Downing²  Jacqueline Guidry²  Michael Lee²  Stephen K. Tyring² 

[1] Department of Dermatology, the University of Texas Health Science Center at Houston, Houston 77030, TX, USA; E-Mail:;Center for Clinical Studies, Houston 77004, TX, USA; E-Mails:

关键词: pharmacotherapy;    HPV;    warts;    condyloma;    treatment;   

DOI  :  10.3390/jcm4050832

来源: mdpi

【 摘 要 】

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.